NO20072325L - Kombinasjonsterapi omfattende telmisartan og hydroklortiazid - Google Patents

Kombinasjonsterapi omfattende telmisartan og hydroklortiazid

Info

Publication number
NO20072325L
NO20072325L NO20072325A NO20072325A NO20072325L NO 20072325 L NO20072325 L NO 20072325L NO 20072325 A NO20072325 A NO 20072325A NO 20072325 A NO20072325 A NO 20072325A NO 20072325 L NO20072325 L NO 20072325L
Authority
NO
Norway
Prior art keywords
hydrochlorothiazide
telmisartan
combination therapy
therapy including
approx
Prior art date
Application number
NO20072325A
Other languages
English (en)
Inventor
Axel Riedel
Helmut E Schumacher
Peter Boehm
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072325(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20072325L publication Critical patent/NO20072325L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

Et farmasøytisk preparat omfattende ca. 80 mg telmisartan og ca. 25 mg hydroklortiazid eller ca. 160 mg telmisartan og ca. 50 mg hydroklortiazid for behandling av hypertensjon hos pasienter med en utilstrekkelig blodtrykkreduksjon etter behandling enten med en angiotensin II-reseptorantagonist eller et farmasøytisk preparat av en angiotensin II-reseptorantagonist og en lav dose av hydroklortiazid.
NO20072325A 2004-12-17 2007-05-04 Kombinasjonsterapi omfattende telmisartan og hydroklortiazid NO20072325L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17
PCT/EP2005/013224 WO2006063737A1 (en) 2004-12-17 2005-12-09 Combination therapy comprising telmisartan and hydrochlorothiazide

Publications (1)

Publication Number Publication Date
NO20072325L true NO20072325L (no) 2007-07-06

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072325A NO20072325L (no) 2004-12-17 2007-05-04 Kombinasjonsterapi omfattende telmisartan og hydroklortiazid

Country Status (15)

Country Link
EP (1) EP1827424A1 (no)
JP (1) JP2008524136A (no)
KR (1) KR20070097511A (no)
CN (1) CN101080225A (no)
AR (1) AR052052A1 (no)
AU (1) AU2005315855A1 (no)
BR (1) BRPI0519656A2 (no)
CA (1) CA2589493A1 (no)
EA (1) EA200701159A1 (no)
IL (1) IL183944A0 (no)
NO (1) NO20072325L (no)
PE (1) PE20060768A1 (no)
TW (1) TW200637546A (no)
UY (1) UY29274A1 (no)
WO (1) WO2006063737A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
ES2406939T3 (es) * 2007-10-19 2013-06-10 Otsuka Pharmaceutical Co., Ltd. Preparación farmacéutica de matriz sólida
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
PL2252273T3 (pl) 2008-03-19 2017-07-31 Ratiopharm Gmbh Stała kompozycja farmaceutyczna zawierająca niepeptydowy związek antagonistyczny receptora angiotensyny II i środek moczopędny
CA2732018C (en) 2008-07-31 2017-07-04 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
WO2011002425A2 (en) * 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
WO2011002423A2 (en) * 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
JP6379044B2 (ja) * 2013-01-31 2018-08-22 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
ES2847904T3 (es) * 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicamento para la prevención o el tratamiento de la hipertensión
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
ES2298351T5 (es) * 2002-01-16 2012-01-26 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Método para producir un comprimido farmacéutico de dos capas que comprenden telmisartán e hidroclorotiazida.

Also Published As

Publication number Publication date
AU2005315855A1 (en) 2006-06-22
EP1827424A1 (en) 2007-09-05
CA2589493A1 (en) 2006-06-22
BRPI0519656A2 (pt) 2009-03-03
UY29274A1 (es) 2006-07-31
PE20060768A1 (es) 2006-09-29
IL183944A0 (en) 2007-10-31
EA200701159A1 (ru) 2007-12-28
TW200637546A (en) 2006-11-01
AR052052A1 (es) 2007-02-28
WO2006063737A1 (en) 2006-06-22
JP2008524136A (ja) 2008-07-10
KR20070097511A (ko) 2007-10-04
CN101080225A (zh) 2007-11-28

Similar Documents

Publication Publication Date Title
NO20072325L (no) Kombinasjonsterapi omfattende telmisartan og hydroklortiazid
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
EP2248519A3 (en) Non-mucoadhesive film dosage forms
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
JP5899165B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
RU2010135831A (ru) Способы, лекарственные формы и наборы для введения зипрасидона без пищи
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
MXPA05008461A (es) Equipo para aplicar revestimiento de farmaco a un dispositivo medico en un cuarto del cirujano.
AR034517A1 (es) Formulacion farmaceutica
WO2010045417A3 (en) Combination therapies for the treatment of obesity
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
WO2007098387A3 (en) Antihypertensive therapy
JP7109092B2 (ja) リドカインおよびジクロフェナクを含む神経障害性疼痛の治療用の医薬用貼付剤
MX2023000303A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
WO2004096118A3 (en) Composition for improving cognition and memory
CL2007003484A1 (es) Composicion farmaceutica que comprende valsartan y un tensoactivo, un componente lipofilico y un componente hidrofilico; procedimiento de preparacion; y uso en el tratamiento de la insuficiencia cardiaca, angina, infarto de miocardio, arterioescleros
Moore et al. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure
SE9902597D0 (sv) New use
WO2004037199A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
JP7109093B2 (ja) リドカインおよびジクロフェナクを含む医薬用貼付剤についての投与計画
NO20061515L (no) Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
PT1408977E (pt) Terapia de combinacao para o tratamento de falha cardiaca
WO2009061445A3 (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
TH83710B (th) การบำบัดรวม

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application